Cisplatin monotherapy effective in pediatric high-risk hepatoblastoma
As reported in the Journal of Pediatric Hematology/Oncology, treatment of children with high-risk hepatoblastoma (n=14) with cisplatin monotherapy was as effective as cisplatin + doxorubicin combination therapy, but with less toxicity. The complete resection rate was 78.6%, the event-free survival rate was 81.8%, and the OS rate was 100%.
YKL-40 predicts poor prognosis for bladder cancer
As reported in Urologic Oncology, the gene expression and serum level of YKL-40 are higher in patients with bladder cancer than healthy controls. Serum YKL-40 levels predict poor prognosis in patients with muscle-invasive bladder cancer (HR=1.75).
CHD7 associated with survival in pancreatic ductal adenocarcinoma patients receiving gemcitabine
As reported in Cancer Research, low CHD7 expression is associated with increased RFS and OS in pancreatic ductal adenocarcinoma patients receiving gemcitabine. There was no association between CHD7 expression and RFS or OS in patients who were not treated with gemcitabine.